Amid financial turbulence and rumors of an imminent sale of assets to pare its debt pile, India's Wockhardt Ltd. gave its investors something to cheer about in the new year.
The Mumbai-based firm has received regulatory approval in India for two indigenously developed novel antibiotics, essentially broad spectrum anti-MRSA drugs, which it claims provide a far better safety profile than existing therapies
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?